FibroGen Reports Positive Topline Results From Phase 2 Study Of Roxadustat

(RTTNews) - FibroGen, Inc. (FGEN) on Wednesday announced positive topline results from the Phase 2 study of roxadustat, dubbed Whitney, in chemotherapy-induced anemia (CIA).

Phase 2 study of roxadustat for the treatment of anemia in patients receiving concurrent chemotherapy treatment for non-myeloid malignancies has been met the primary efficacy endpoint of maximum change in hemoglobin within 16 weeks from baseline without red blood cell transfusion.

Roxadustat is a first-in-class oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI).

FibroGen said roxadustat was well tolerated and there were no substantive differences in treatment-emergent adverse events between arms with different starting doses.

Complete results of the study is expected to be presented at a medical meeting later this year.